Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Manhattan Scientifics’ Technology Able to Detect Breast Cancer Three Years Earlier Than Mammogram

Abstract:
New Technology 100% Radiation Free

Manhattan Scientifics’ Technology Able to Detect Breast Cancer Three Years Earlier Than Mammogram

Albuquerque, NM | Posted on April 22nd, 2010

Manhattan Scientifics, Inc. (OTCBB: MHTX) announced today that its "early cancer detection" technology, developed by Edward R. Flynn, Ph.D. is expected to identify breast cancer three years earlier than the current gold standard mammogram test. Dr. Flynn is a pioneer in the emerging field of nanomedicine.

When fully developed and commercialized, Dr. Flynn's biomagnetic-based system will be 100% radiation free, unlike current radiation-based mammogram tests. Manhattan Scientifics is currently seeking a partner to commercialize the technology.

To reduce harm from over-treatment and radiation, new medical guidelines recently issued by the U.S. Preventive Services Task Force recommended that women begin regular breast cancer screening at age 50, rather than age 40. "Annual mammograms for most women in their 40's have more drawbacks than benefits...." according to an article published by Bloomberg News, November 17, 2009.

CEO Manny Tsoupanarias said, "We believe early detection of cancer can be critical to effective treatment. Current mammography cannot detect a breast cancer tumor until it has grown to over ten million cells. Dr. Flynn's technology has proven the ability to detect breast cancer tumors only 1% that large, resulting in a hundred-fold increase in sensitivity and early detection.

"The new technology has demonstrated similar early detection performance for ovarian cancer, a cancer that currently has no effective screening techniques. Our technology also demonstrated effectiveness in monitoring chemotherapy for leukemia, allowing more effective treatment with fewer side effects. Dr. Flynn's work has been supported for eight years by nine grants from the National Institutes of Health and a grant from the U.S. Department of Defense. The technology is protected by issued and pending patents," Tsoupanarias said.

Dr. Flynn said, "Our approach uses sophisticated magnetic field sensors to measure extremely small magnetic fields emitted by magnetic nanoparticles that have been injected into the body and targeted specifically toward cancer cells. This method yields high contrast images of tumors compared to normal cells. With this biomagnetic imaging technique, it is possible to identify and image tiny clusters of cancer cells, providing the ability to find cancer at a substantially earlier stage than is presently possible. This has a distinct advantage over other imaging methods in that it detects only particles bound to targeted cells and is not sensitive to unbound particles where other methods may be overwhelmed by the unbound particles. It is done without the use of ionizing radiation. This biomagnetic sensor method is applicable to breast, ovarian, leukemia, prostate and potentially to many other cancers."

Tsoupanarias added, "As an inventions company, our strategy is to partner with large, well financed, experienced manufacturers and marketers. Manhattan Scientifics typically receives royalty income and fixed fees from its industrial partner. Our new class of metals nano-technology business is a clear and profitable example of our business model. We have a long way to go with our early cancer technology, but we are excited about the obvious prospects, both for the overall improvement of early cancer detection as well as for our own business."

On February 25, 2010, Manhattan Scientifics announced that it had acquired exclusive rights to commercialize Dr. Flynn's work.

Forward looking statement This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected. Factors that may cause actual results and outcomes to differ materially are described in our publicly filed reports including, but not limited to, failure to realize projected revenues and cash flows, market conditions and other factors that could negatively affect the market for our technology. . We undertake no obligation to publicly update or revise any forward-looking statements.

####

About Manhattan Scientifics
Manhattan Scientifics, Inc. operates with locations in New Mexico, New York, and Montreal. The company’s goal is to advance and commercialize disruptive technologies to create profit for its shareholders in the field of nanomedicine.

For more information, please click here

Contacts:
Manhattan Scientifics, Inc.
Marvin Maslow, Director of PR & IR, 917-923-3300


European Contact:
Herbert Strauss, +43-316-296-316


IR:
Hawk Associates
Frank Hawkins, 305-451-1888

Copyright © Business Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Special UO microscope captures defects in nanotubes: University of Oregon chemists provide a detailed view of traps that disrupt energy flow, possibly pointing toward improved charge-carrying devices October 21st, 2014

Super stable garnet ceramics may be ideal for high-energy lithium batteries October 21st, 2014

Could I squeeze by you? Ames Laboratory scientists model molecular movement within narrow channels of mesoporous nanoparticles October 21st, 2014

Detecting Cancer Earlier is Goal of Rutgers-Developed Medical Imaging Technology: Rare earth nanocrystals and infrared light can reveal small cancerous tumors and cardiovascular lesions October 21st, 2014

Possible Futures

Imaging electric charge propagating along microbial nanowires October 20th, 2014

Superconducting circuits, simplified: New circuit design could unlock the power of experimental superconducting computer chips October 18th, 2014

Nanocoatings Market By Product Is Expected To Reach USD 8.17 Billion By 2020: Grand View Research, Inc. October 15th, 2014

Perpetuus Carbon Group Receives Independent Verification of its Production Capacity for Graphenes at 140 Tonnes per Annum: Perpetuus Becomes the First Manufacturer in the Sector to Allow Third Party Audit October 7th, 2014

Nanomedicine

Detecting Cancer Earlier is Goal of Rutgers-Developed Medical Imaging Technology: Rare earth nanocrystals and infrared light can reveal small cancerous tumors and cardiovascular lesions October 21st, 2014

Design of micro and nanoparticles to improve treatments for Alzheimers and Parkinsons: At the Faculty of Pharmacy of the UPV/EHU-University of the Basque Country encapsulation techniques are being developed to deliver correctly and effectively certain drugs October 20th, 2014

Non-Toxic Nanocatalysts Open New Window for Significant Decrease in Reaction Process October 19th, 2014

European Commission opens the gate towards the implementation of Nanomedicine Translation Hub October 16th, 2014

Announcements

Special UO microscope captures defects in nanotubes: University of Oregon chemists provide a detailed view of traps that disrupt energy flow, possibly pointing toward improved charge-carrying devices October 21st, 2014

Super stable garnet ceramics may be ideal for high-energy lithium batteries October 21st, 2014

Could I squeeze by you? Ames Laboratory scientists model molecular movement within narrow channels of mesoporous nanoparticles October 21st, 2014

Detecting Cancer Earlier is Goal of Rutgers-Developed Medical Imaging Technology: Rare earth nanocrystals and infrared light can reveal small cancerous tumors and cardiovascular lesions October 21st, 2014

Patents/IP/Tech Transfer/Licensing

Nanodevices for clinical diagnostic with potential for the international market: The development is based on optical principles and provides precision and allows saving vital time for the patient October 15th, 2014

Aculon Receives Patent for Application of Enhanced Bonding Layers on Titanium October 9th, 2014

harmaEngine will join Nanobiotix’ pivotal trial for NBTXR3 in Soft Tissue Sarcoma to accelerate its development in Asia-Pacific: PharmaEngine to make milestone payment to Nanobiotix in October 2014 to recognize the value created October 8th, 2014

‘Small’ transformation yields big changes September 16th, 2014

Nanobiotechnology

Crystallizing the DNA nanotechnology dream: Scientists have designed the first large DNA crystals with precisely prescribed depths and complex 3D features, which could create revolutionary nanodevices October 20th, 2014

Scientists Map Key Moment in Assembly of DNA-Splitting Molecular Machine: Crucial steps and surprising structures revealed in the genesis of the enzyme that divides the DNA double helix during cell replication October 15th, 2014

DNA nano-foundries cast custom-shaped metal nanoparticles: DNA's programmable assembly is leveraged to form precise 3D nanomaterials for disease detection, environmental testing, electronics and beyond October 10th, 2014

Charged graphene gives DNA a stage to perform molecular gymnastics October 9th, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE